spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

BioIVT Launches Dissociated Tumor Cell DTC Product Line to Advance Oncology Research

DTCs are primary cancer cells that are prepared with minimal manipulation and closely mimic tumor behavior.

Westbury, NY – Sept. 6, 2018 – BioIVT, a leading provider of research models and services for drug development, today announced the addition of a dissociated tumor cell (DTC) product line to its immunology portfolio.

“DTCs are patient-derived primary tumor cells isolated from fresh tumor tissue using only mechanical and enzymatic dissociation. As a result of this minimal manipulation, DTCs most closely resemble the tumor and are extremely valuable tools for oncology research,” said BioIVT Sr. Director, Biological Operations Wini Luty, MS. “Since BioIVT acquired Asterand Bioscience™ in August 2017, we have gained greater access to disease-state tissue. As a result, we are now able to provide more tissue product derivatives, such as DTCs, to meet our clients’ specific research needs.”

Researchers can use patient-derived DTCs to determine how specific cohorts of cancer cells will react to different drug therapies. DTCs provide the closest representation of the clinical scenario. While no two patients’ tumors are identical, there is a greater likelihood of a therapy being effective if it has been previously tested on DTCs from patients with similar donor demographics and health issues. In this way, DTCs can help to advance personalized medicine.

DTCs can also be incorporated into 3D micro-tumor arrays to provide highly efficient, high-throughput drug screening and chemosensitivity testing.

BioIVT is initially providing DTC lots from kidney, ovarian, liver, breast, colon, and lung tumors. Clients can also request matched sets of DTCs with peripheral blood mononuclear cells, normal tumor-adjacent tissue or tumor tissue.

As offering high-quality products is a BioIVT top priority, a pathologist reviews each tumor sample at collection to confirm that it is the correct tissue and organ site and that the diagnosis matches the clinical data.

BioIVT quality control processes also ensure that all the cell lots are sterile and pathogen-free. In addition, a small portion of cells from each lot are thawed and grown to confluency in cell culture to ensure that they are viable and will grow as expected by the client. All such information is detailed on the Certificate of Analysis accompanying the cell lot.

About BioIVT

BioIVT, formerly BioreclamationIVT, is a leading global provider of research models and value-added research services for drug discovery and development. We specialize in control and disease-state biospecimens including human and animal tissues, cell products, blood and other biofluids. Our unmatched portfolio of clinical specimens directly supports precision medicine research and the effort to improve patient outcomes by coupling comprehensive clinical data with donor samples. Our PHASEZERO® Research Services team works collaboratively with clients to provide target and biomarker validation, phenotypic assays to characterize novel therapeutics, clinical assay development and in vitro hepatic modeling solutions. And as the premier supplier of ADME-toxicology model systems, including hepatocytes and subcellular fractions, BioIVT enables scientists to better understand the pharmacokinetics and drug metabolism of newly-discovered compounds and their effects on disease processes. By combining our technical expertise, exceptional customer service, and unparalleled access to biological specimens, BioIVT serves the research community as a trusted partner in elevating science. For more information, please visit www.bioivt.com or follow the company on Twitter @BioIVT.
 
Print this page
Send to a friend
   
spacer
News and Press Releases

2019 Pharmapack Awards

Pharmapack Europe have announced entries for the 2019 Pharmapack Awards are now open across both the ‘Exhibitor Innovation’ and ‘Health Products’ categories with a closing date of 30th November 2018. The Health Products category will include two winners with one for Patient-Centric Design – which is launched in partnership with HCPC Europe (Healthcare Compliance Packaging Council of Europe) – and a second introduced alongside Adelphe for Eco-design in health packaging and drug delivery devices. Pharmapack Europe have also announced that they’re accepting applications for the start-up hub which provides young start-up companies servicing the pharma industry with the benefit of valuable networking and learning opportunities at half the price of a regular stand.
More info >>


White Papers

The Flexible Factory Concept: A flexible bioprocessing platform to meet the changing needs of biomanufacturing

GE Healthcare Life Sciences

For the past several years, the biopharma industry has been buffeted by dynamic market conditions that are rapidly reshaping manufacturing requirements. These factors include: • The rise of small-market pharmaceuticals that do not require the production scale of the previous “blockbuster” drug model • Increased titers and process productivity that generate more bulk-product within a much smaller manufacturing footprint • The emergence of biosimilars and continued evolution of healthcare reform, which will increasingly pressure drug pricing and require greater cost discipline • Greater competition and shorter patent protection timelines, which will further ratchet up time-to-market pressures • Tighter capital markets that will create heightened scrutiny for all new investment projects
More info >>

Industry Events

Partnerships in Clinical Trials Europe 2018

27-29 November 2018, CCIB, Barcelona

Partnerships in Clinical Trials Europe is back – and bigger than ever. Europe’s most complete clinical meeting is bringing together 1000+ of the industry’s leading experts this November for it’s 17th annual gathering, and you’re invited!
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement